menu
    • menu
    [{"orgOrder":0,"company":"Cytonics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CYT-108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cytonics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cytonics \/ Not Applicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CYT-108","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cytonics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cytonics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cytonics

    Menu

    Cytonics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytonics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cytonics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-108

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cytonics Completes Enrollment for Phase 1 Study of CYT-108 in Osteoarthritis Patients

                            Details : CYT-108, a recombinant variant of the endogenous alpha-2-macroglobuling protease inhibitor, being investigated for osteoarthritis of the knee.

                            Brand Name : CYT-108

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 06, 2024

                            Lead Product(s) : CYT-108

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytonics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cytonics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-108

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cytonics Initiates Phase 1 Study of CYT-108 for Knee Osteoarthritis

                            Details : CYT-108 is a recombinant variant of the endogenous alpha-2-macroglobulin (A2M) blood serum protein, targeting proteases responsible for cartilage degradation in osteoarthritis.

                            Brand Name : CYT-108

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 15, 2024

                            Lead Product(s) : CYT-108

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth